



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 55059

Title: Novel Molecular Targets in Hepatocellular Carcinoma

Reviewer's code: 02944288

Position: Editorial Board

Academic degree: MD

Professional title: Assistant Professor, Lecturer, Surgeon

Reviewer's Country/Territory: Russia

Author's Country/Territory: China

Manuscript submission date: 2020-02-28

Reviewer chosen by: Jin-Zhou Tang (Quit in 2020)

Reviewer accepted review: 2020-03-21 14:33

Reviewer performed review: 2020-03-24 04:55

Review time: 2 Days and 14 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

the manuscript could be published



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 55059

Title: Novel Molecular Targets in Hepatocellular Carcinoma

Reviewer's code: 00503536

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2020-02-28

Reviewer chosen by: Ruo-Yu Ma

Reviewer accepted review: 2020-04-14 06:53

Reviewer performed review: 2020-04-16 05:45

Review time: 1 Day and 22 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The review written by Chow A, K-M, et al. describes the advances in the novel molecular targets in hepatocellular carcinoma (HCC). The authors summarize the novel drugs targeting specific molecules for the treatment of HCC, and give explanations of the mechanisms for the anti-HCC effect in each drug. However, there are no descriptions regarding the results of anti-HCC effect in the animal model or human studies. Moreover, how those drugs are placed in various guideline of the treatment of HCC is not described.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 55059

Title: Novel Molecular Targets in Hepatocellular Carcinoma

Reviewer's code: 00053419

Position: Editorial Board

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: Spain

Author's Country/Territory: China

Manuscript submission date: 2020-02-28

Reviewer chosen by: Ruo-Yu Ma

Reviewer accepted review: 2020-04-16 14:48

Reviewer performed review: 2020-04-27 02:44

Review time: 10 Days and 11 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

To the Authors The manuscript reviews the current therapeutic options for HCC as well as some new options based on specific molecular targets. Although it does not get into much detail, the manuscript summarizes the most relevant information in the field in a very comprehensive manner. I would just suggest to include a schema with the front-line therapeutic options for HCC, then the second line, etc and the upcoming strategies, including the targets involved. This would allow the reader for a rapid analysis of the current status of HCC treatment.